IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDEAYA Biosciences Inc.

Ideaya Biosciences ($IDYA) announced an update on their ongoing clinical study. Ideaya Biosciences is running a new study to test its drug IDE574 i...

Ideaya’s IDE574 Trial Signals New Optionality in Advanced Solid Tumors and Breast Cancer

LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences yesterday and set a price target of $62.00. According to TipRanks...

IDEAYA Biosciences (IDYA) Receives a Buy from LifeSci Capital

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IDEAYA Biosciences (IDYA), Ardent Health Partners, I...

Analysts Are Bullish on Top Healthcare Stocks: IDEAYA Biosciences (IDYA), Ardent Health Partners, Inc. (ARDT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lineage Therap (LCTX), IDEAYA Biosciences (IDYA) and...

Market Cap	$2.50B	P/E Ratio	N/A
52W High	$39.28	52W Low	$18.77
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	3.4%	52W Position	51.5%
Overall Score	40	Value Score	60
Quality Score	50	Technical Score	10

EPS Current Est	$-4.28	EPS Next Est	$-3.9
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IDYA	$29.34	+0.20%	584.54K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IDYA	$29.34	+0.2%	584.54K
3
4
5
6

IDYA

IDYA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get IDEAYA Biosciences Inc. Data in Excel

Get IDEAYA Biosciences Inc. Data in Excel